

Syntara receives A\$1.7m SNT-4728 milestone payment from Parkinson's UK

Syntara Limited (ASX: SNT), a clinical-stage drug development company, is pleased to announce that it has received a milestone payment of approximately A\$1.7 million (£900,000) from Parkinson's UK, triggered by dosing of the final patient in its Phase 2 clinical trial of SNT-4728.

The payment forms part of Parkinson's UK's funding commitment to support the development of SNT-4728, which is being evaluated as a potential treatment targeting neuroinflammation associated with early-stage Parkinson's disease.

The Phase 2 trial is evaluating SNT-4728 in individuals diagnosed with isolated REM sleep behaviour disorder (iRBD), a condition recognised as one of the strongest known early indicators of future Parkinson's disease and related neurodegenerative disorders. More than 80% of iRBD patients go on to develop Parkinson's disease¹ and the related disorders dementia with Lewy bodies and multiple system atrophy.

Top-line results from the trial, including both safety and efficacy endpoints, are expected in Q2 CY26. Syntara will be eligible to receive a further A\$0.45 million (£250,000) milestone payment from Parkinson's UK upon project completion. The global addressable market for iRBD is estimated at US\$1.6b² and for Parkinson's disease at US\$9.2b by 2030³.

¹ <https://doi.org/10.1007/s11910-022-01171-0>

² <https://www.researchandmarkets.com/reports/6106549/rem-sleep-behavior-disorders-global-strategic>

³ https://www.bccresearch.com/market-research/pharmaceuticals/anti-parkinson-drugs-global-markets-report.html?utm_source=PRGNPHM193B&utm_medium=referral&utm_campaign=prgnw

#ENDS#

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol® - a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

SOURCE:

Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:

Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST [HERE](#)

